VIR Valuation

Vir Biotechnology Inc

Add to Watchlist

Advanced Chart

5.180

+0.38(7.917%)1D

Overview
Forecast
Valuation
Earnings

VIR Relative Valuation

VIR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VIR is overvalued; if below, it's undervalued.

Historical Valuation

Vir Biotechnology Inc (VIR) is now in the Overvalued zone, suggesting that its current forward PS ratio of 76.65 is considered Overvalued compared with the five-year average of -6.73. The fair price of Vir Biotechnology Inc (VIR) is between 0.79 to 2.73 according to relative valuation methord. Compared to the current price of 4.80 USD , Vir Biotechnology Inc is Overvalued By 75.58%.

Relative Value

Fair Zone

0.79-2.73

Current Price：4.80

75.58%

Overvalued

-1.63

Trailing

Forward

-0.38

EV/EBITDA

Vir Biotechnology Inc. (VIR) has a current EV/EBITDA of -0.38. The 5-year average EV/EBITDA is -3.05. The thresholds are as follows: Strongly Undervalued below -27.81, Undervalued between -27.81 and -15.43, Fairly Valued between 9.33 and -15.43, Overvalued between 9.33 and 21.71, and Strongly Overvalued above 21.71. The current Forward EV/EBITDA of -0.38 falls within the Historic Trend Line -Fairly Valued range.

-0.34

EV/EBIT

Vir Biotechnology Inc. (VIR) has a current EV/EBIT of -0.34. The 5-year average EV/EBIT is -5.24. The thresholds are as follows: Strongly Undervalued below -40.15, Undervalued between -40.15 and -22.70, Fairly Valued between 12.22 and -22.70, Overvalued between 12.22 and 29.67, and Strongly Overvalued above 29.67. The current Forward EV/EBIT of -0.34 falls within the Historic Trend Line -Fairly Valued range.

75.71

Vir Biotechnology Inc. (VIR) has a current PS of 75.71. The 5-year average PS is 24.16. The thresholds are as follows: Strongly Undervalued below -14.67, Undervalued between -14.67 and 4.74, Fairly Valued between 43.57 and 4.74, Overvalued between 43.57 and 62.99, and Strongly Overvalued above 62.99. The current Forward PS of 75.71 falls within the Strongly Overvalued range.

-2.05

P/OCF

Vir Biotechnology Inc. (VIR) has a current P/OCF of -2.05. The 5-year average P/OCF is 4.34. The thresholds are as follows: Strongly Undervalued below -77.90, Undervalued between -77.90 and -36.78, Fairly Valued between 45.46 and -36.78, Overvalued between 45.46 and 86.58, and Strongly Overvalued above 86.58. The current Forward P/OCF of -2.05 falls within the Historic Trend Line -Fairly Valued range.

-1.62

P/FCF

Vir Biotechnology Inc. (VIR) has a current P/FCF of -1.62. The 5-year average P/FCF is 6.95. The thresholds are as follows: Strongly Undervalued below -85.52, Undervalued between -85.52 and -39.28, Fairly Valued between 53.19 and -39.28, Overvalued between 53.19 and 99.42, and Strongly Overvalued above 99.42. The current Forward P/FCF of -1.62 falls within the Historic Trend Line -Fairly Valued range.

Vir Biotechnology Inc (VIR) has a current Price-to-Book (P/B) ratio of 0.70. Compared to its 3-year average P/B ratio of 1.05 , the current P/B ratio is approximately -32.92% higher. Relative to its 5-year average P/B ratio of 2.85, the current P/B ratio is about -75.30% higher. Vir Biotechnology Inc (VIR) has a Forward Free Cash Flow (FCF) yield of approximately -69.08%. Compared to its 3-year average FCF yield of -24.64%, the current FCF yield is approximately 180.32% lower. Relative to its 5-year average FCF yield of -12.95% , the current FCF yield is about 433.34% lower.

0.70

P/B

Median3y

1.05

Median5y

2.85

-69.94

FCF Yield

Median3y

-24.64

Median5y

-12.95

Competitors Valuation Multiple

The average P/S ratio for VIR's competitors is 37.86, providing a benchmark for relative valuation. Vir Biotechnology Inc Corp (VIR) exhibits a P/S ratio of 75.71, which is 99.96% above the industry average. Given its robust revenue growth of -60.52%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

VIR.O

Vir Biotechnology Inc

Nurix Therapeutics Inc

Relay Therapeutics Inc

121.64

784.47M

MRVI.O

Maravai LifeSciences Holdings Inc

Performance Decomposition

Market capitalization of VIR decreased by 35.91% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -4.50K to -9.14K.

The secondary factor is the Revenue Growth, contributed -60.52%to the performance.

Overall, the performance of VIR in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-60.52%

3.08M → 1.21M

Revenue Growth

103.10%

-4.50K → -9.14K

Margin Expansion

-78.49%

-5.57 → -1.20

P/E Change

-35.91%